An interventional study of 177Lu-PSMA-617 + SPECT/CT dosimetry in Carcinoma and Castration Resistant Prostatic Neoplasms, sponsored by Centre Henri Becquerel. Not yet recruiting at 1 site in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Centre Henri Becquerel · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Carcinoma with a site in France — 20 open to participants now, 32 under way, 14 of them phase 3. Carcinoma · France.
Among the 105 studies in Carcinoma with a site in France, this one is the 54th largest by planned enrollment of the 86 interventional ones that give a count, is one of 8 that started in 2026, is one of 7 with no phase, reaches primary completion later than 23 of the 31 other live ones, and was the 103rd registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →20 of the 105 studies in Carcinoma with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Australia and 13 more countries
Ages 18+
Pfizer · Sites in France, United States, Australia and 11 more countries
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Hôpital NOVO · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Argentina and 18 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 31 · Phase 3 37 · Phase 4 1
First in 1999; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 171 across the 86 interventional studies, 279 across the 19 observational. Of the 66 that completed or were terminated, 28 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 105 have an industry lead sponsor. The 10 most frequent:
Centre Henri Becquerel is the lead sponsor of 59 studies on the registry; 17 are open to participants now.
Centre Henri Becquerel has 1 study filed under Carcinoma — fewer than ten, so there is no comparison to draw.
5 of the studies in Carcinoma with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT07201012Centre Hospitalier Universitaire de NīmesDetermining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome | 2026-11 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
| NCT07257094Hôpital NOVONasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer | 2027-07-30 |
| NCT05592626Marengo Therapeutics, Inc.A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 105 studies in Carcinoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.
Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. 177Lu-PSMA-617 is a radioligand therapy delivering beta-particle radiation to PSMA-expressing cells. The VISION trial demonstrated significant improvement in progression-free and overall survival compared to standard of care.
Hypotheses: patients with higher fat mass may have better treatment response due to higher tumor dose; discordance between BMI-based and CT-based body composition measurements; SUV quantification in PET/CT and SPECT/CT depends on patient morphology; dosimetry of organs at risk depends on morphology; body composition changes during treatment; PSA kinetics are modified by dosimetry.
Study design: patients scheduled for 177Lu-PSMA treatment (4 or 6 cycles, 7400 MBq IV every 6 weeks) are enrolled. After cycle 1, SPECT/CT is performed at 72-96H (all patients) and additionally at 4-24H and 168-196H (40 patients for multipoint dosimetry). Body composition is extracted from the non-injected CT component of SPECT/CT using Anthropometer3DNet. Nutritional assessment (MNA questionnaire, blood tests including albumin, transthyretin, CRP, PSA) is performed at baseline (C1) and end of treatment (C4 or C6).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with mCRPC treated with 177Lu-PSMA-617 undergoing additional SPECT/CT acquisitions and body composition analysis
Radiation: 177Lu-PSMA-617 + SPECT/CT dosimetry
177Lu-PSMA-617 7400 MBq IV, 4 to 6 cycles every 6 weeks (standard of care). Additional interventions: whole-body SPECT/CT at 4-24H and/or 168-196H post-injection (research acquisitions) for dosimetry. Body composition analysis from SPECT/CT scanner using Anthropometer3DNet. MNA questionnaire and nutritional blood tests at baseline and end of treatment.
Tumor and organ-at-risk dosimetry as a function of body composition
Dosimetry (Gy) of all tumors and organs at risk (salivary glands, bone marrow, kidneys) evaluated by SPECT/CT at 72-96H post-injection. Patients classified into two categories based on median body composition of the study population.
Time frame: After cycle 1 of 177Lu-PSMA treatment (approximately week 1)
Comparison of SUV vs SUL in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT
Comparison of SUV (normalized by total body mass) and SUL (normalized by lean body mass) of lesions and organs at risk. Difference \<20% considered equivalent.
Time frame: Baseline and after cycle 1 (approximately week 1)
Evaluate the differences between a single-point dosimetric approach based on population pharmacokinetics and a multi-point approach
Comparison of dosimetry
Time frame: 196 hours after the injection of the first cycle of 177LuPSMA
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.
Of 29 interventional studies with no phase under Carcinoma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Henri Becquerel